Compare Medtronic PLC (MDT) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Victoria's Secret & Co — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while Victoria's Secret & Co trades at $82.86 (market cap $6.91B). The key difference: Medtronic PLC is far larger — about 16.2× Victoria's Secret & Co's market cap, and Medtronic PLC pays a 3.28% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Victoria's Secret & Co for 34 Days on average.
| MDT | VSXY | |
|---|---|---|
Market Cap | $112.24B | $6.91B |
Volume | 105,663,236 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $99.97 |
52-Week Low | $73.75 | $28.25 |
Typical Hold Time | 63 Days | 34 Days |
Enterprise Value | $131.58B | $9.29B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
Victoria's Secret (VSXY) trades at $81.83, down 4.62% today, but maintains strong technical momentum with a bullish moving average signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE. Recent news highlights the fashion show expansion and omnichannel growth strategy driving international sales momentum. Cash flow projections for 2026 show significant improvement to $334M net cash flow, indicating stronger financial health ahead.
The stock presents a compelling opportunity with 60% analyst buy ratings and an $86.80 consensus target offering 6% upside. However, elevated valuation multiples and recent margin pressure require careful monitoring. The company's Path to Potential initiative shows promising traction, but execution risks and competitive retail pressures remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
